products like zytega for prostate cancer. another product that's recently launched is zyrelto in our cardiovascular area. we're working on key coronary syndrome. we're expanding on the hiv platform. >> the medical device business more than any other business is closely tied to economics. so when things went down in 2008, you really saw a sharp impact on that business. how's it going? >> it is unique that over the last few years, particularly with the significant macro economic issues and the economic downturn, i think we have some pretty good insights into what's happening with utilization. and for the first time since we've been tracking data, we actually saw elasticity in demand relative to what was going on with the economy. but whether you looked at hips, knees, sports medicine, all the aesthetics particularly, anything where there was an elective nature to the procedure, or people could de r defer, delay procedures, due to not being insured, being unemployed, being concerned about the environment, we saw a drop in those